Senior Director, Managed Access Programs, Medical Evidence Generation (Worldwide Medical Affairs) at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Degree in a relevant field (e.g., Life Sciences, Patient Access, Pharmacy, Public Health) required
Minimum of 7+ years of experience in the pharmaceutical or biotechnology industry
At least 3 years in a role related to managed access
Proven track record of successfully managing Managed Access Programs (MAPs) across a disease area

Responsibilities

Collaborate with key partners (WW TA, DD, legal, compliance, RCO, Country medical teams) to define and develop the managed access strategy for assets across multiple disease areas
Ensure the managed access strategy has input from all required partners and goes through the appropriate review and governance processes
Partner with GDO/RCO to ensure seamless operationalization of managed access programs for respective disease areas, ensuring appropriate country rules are followed
Implement standardized policies, procedures, and best practices across the portfolio of managed access programs
Establish and track key performance indicators (KPIs) to measure the success of the managed access programs and leverage data and analytics to optimize MAPs and accelerate impact
Serve as the primary point of contact for internal (Medical Affairs, Development, Commercial, Regulatory Affairs, Legal, and Compliance) and external stakeholders to ensure seamless program execution and compliance with global, regional, and local regulations and guidelines
Optimize the capture and utilization of data and evidence from MAPs that appropriately supports the value of BMS’ assets and ensure that data collection processes comply with country-specific regulations and privacy laws
Provide training and support to internal teams on MAP processes and best practices
Foster an innovative culture and lead initiatives to increase innovative approaches to MAPs

Skills

Managed Access Programs

Medical Affairs

Strategic Planning

Global Implementation

Regulatory Compliance

Cross-Functional Collaboration

Health Equity

Patient Access

Policy Development

Data Capture

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free